EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Sponsor
NHS Greater Glasgow and Clyde
Study ID
NCT05020704
Phase
PHASE3
Status
Unknown

Conditions

  • Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The addition of the SGLT2 inhibitor empagliflozin 10mg once daily to standard-of-care therapy administered early following acute myocardial infarction will result in a greater attenuation of adverse left ventricular remodelling, compared with matched placebo, in patients with left ventricular systolic dysfunction as a result of an acute myocardial infarction.

Key Dates

Start date
Sep 16, 2022
Status verified
Apr 2024
Primary completion
Jun 12, 2024
Completion
Jun 12, 2024

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: empagliflozin
    empagliflozin 10mg once daily
  • Placebo Comparator: Placebo
    matched placebo

Primary Outcome Measure

Left ventricular end-systolic volume indexed to body surface area (LVESVI) [ Time Frame: 24 weeks ]

Related Studies